Physician profile
Roche M Watson
NPI 1639522659
$3,245.82
in general payments reported to CMS, 2019-2025
31 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.82 · 2022: $327 · 2023: $376 · 2024: $343 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $724.44 | 2023-2025 | |
| Biogen, INC. | $478.43 | 2021-2025 | Tysabri, Vumerity |
| Astrazeneca Pharmaceuticals LP | $239.87 | 2022-2025 | Tezspire, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.95 | 2023 | Spevigo |
| Argenx US, INC. | $146.52 | 2022-2025 | Vyvgart Hytrulo |
| E.R. Squibb & Sons, L.L.C. | $141.38 | 2025 | Zeposia |
| Neurocrine Biosciences, INC. | $130.72 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.40 | 2025 | Caplyta |
| Lilly USA, LLC | $107.62 | 2021-2025 | Kisunla, Amyvid |
| Teva Pharmaceuticals USA, INC. | $106.29 | 2025 | Ajovy, Austedo Xr |
| Amgen INC. | $103.64 | 2023-2025 | Uplizna, Tezspire |
| Pfizer INC. | $95.83 | 2025 | |
| Genentech USA, INC. | $85.19 | 2021-2025 | Ocrevus Zunovo, Gazyva, Ocrevus |
| Novartis Pharmaceuticals Corporation | $69.67 | 2023-2025 | |
| Lundbeck LLC | $55.75 | 2023-2025 | Vyepti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $50.27 | 2025 | Zeposia |
| Eisai INC. | $49.58 | 2024-2025 | |
| Globus Medical, INC. | $48.70 | 2025 | Senza |
| Glaxosmithkline, LLC. | $43.35 | 2023 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $29.59 | 2024 | Glassia |
| Almatica Pharma LLC | $28.76 | 2023 | Gralise |
| Vanda Pharmaceuticals INC. | $25.75 | 2025 | Ponvory |
| Sk Life Science, INC. | $25.38 | 2022 | |
| Horizon Therapeutics Plc | $24.91 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $24.49 | 2025 | Lumryz |
| Alnylam Pharmaceuticals INC. | $24.37 | 2025 | Amvuttra |
| Kyowa Kirin, INC. | $23.57 | 2024 | Nourianz |
| Alexion Pharmaceuticals, INC. | $23.35 | 2022 | |
| Grifols USA, LLC | $20.92 | 2022 | |
| Octapharma USA, INC. | $18.40 | 2024 | Octagam Immune Globulin (Human) |
| Merz Pharmaceuticals, LLC | $15.73 | 2025 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roche Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.